Related Experiment Video
Updated: May 25, 2026
06:16
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
[Cost-effectiveness: euros per QALY is not enough]
Matthijs van den Berg1, Heleen H Hamberg-van Reenen, Casper G Schoemaker
1Rijksinstituut voor Volksgezondheid en Milieu, Centrum voor Volksgezondheid Toekomstverkenningen, Bilthoven, the Netherlands. matthijs.van.den.berg@rivm.nl
Nederlands Tijdschrift Voor Geneeskunde
|February 3, 2012
Summary
Economic evaluations are rising, influencing healthcare decisions. Small changes in cost-effectiveness assumptions significantly alter results, demanding cautious interpretation of analyses.
Area of Science:
- Health Economics
- Decision Science
Context:
- Increasing publication of economic evaluations in scientific literature.
- Growing importance of cost-effectiveness in healthcare reimbursement and intervention implementation.
Purpose:
- To highlight the critical role of assumptions in cost-effectiveness analyses.
- To emphasize the sensitivity of cost-effectiveness ratios to variations in input parameters.
Summary:
- A cost-effectiveness ratio is calculated as costs divided by effects.
- The numerator includes intervention costs, while the denominator considers effectiveness and reach.
- Minor adjustments in assumptions regarding long-term effects or participation rates can substantially impact the ratio.
Impact:
- Underscores the need for careful scrutiny and interpretation of cost-effectiveness analysis outcomes.
- Promotes transparency and critical evaluation of the methodologies behind economic evaluations.
- Informs policymakers and healthcare providers about the potential variability in study findings.
Related Concept Videos
01:16Bioequivalence Data: Statistical Interpretation
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:22Dose-Response Relationship: Potency and Efficacy
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...